Pulmonary hypertension - SAPH
SAPH is pulmonary hypertension associated with sarcoidosis.
It is a common complication of sarcoidosis and is associated with a poor prognosis.
SAPH may result from multiple synergistic mechanisms, and current treatment strategies treat systemic sarcoidosis and pulmonary hypertension separately. Several studies have been conducted to develop an effective treatment for SAPH, but the results have varied.
SAPH is thought to develop as a result of complex interactions between sarcoidosis-related inflammatory processes in the lung parenchyma and pulmonary vasculature.
The mechanisms by which sarcoidosis may cause pulmonary hypertension include:
-hypoxia,
-pulmonary artery vasculitis,
-sarcoidosis-related heart failure, -fibrotic destruction of the pulmonary vasculature, -occlusion of the pulmonary vasculature by granulomatous tissue
-sarcoidosis-induced liver disease
-subsequent portopulmonary hypertension.
Systemic arterial hypertension (high blood pressure)
High blood pressure, or hypertension, occurs when blood pressure rises to an unhealthy level.
Blood-pressure measurement takes into account how much blood passes through your blood vessels and the resistance the blood encounters as your heart pumps.
A diagnosis of high blood pressure is not made on the basis of a single blood-pressure measurement. If a person's blood pressure is measured above 140/90 mmHg on more than three occasions, that person is considered to have high blood pressure.
In general, the symptoms of severe hypertension may include:
- headaches
- shortness of breath
- nosebleeds
- dizziness
- chest pain
- facial flushing
- blood in the urine
Foundation for Sarcoidosis Research
Read more: https://m.facebook.com/groups/sarkoidoza/permalink/1037311286813335/?sfnsn=mo&ref=share